Zanubrutinib Monotherapy for Relapsed or Refractory Non-Germinal Center Diffuse Large B-Cell Lymphoma
Yang, H., et al., Zanubrutinib Monotherapy for Relapsed or Refractory Non-Germinal Center Diffuse Large B-Cell Lymphoma
Categories
Filter by Topics
1L therapy; bispecific antibodies 478P TA-ness ABC- type ADCC Gene Alteration adolescents AI alcohol consumption ALK alzheimer's Angiogenesis Anti-TNF Alpha Therapy antibody drug conjugates antiEGFR aplastic anemia AA Apoptosis apoptosis appendiceal neoplasms Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells B-accute lyphoblastic leukemia B-ALL B-accute lyphoblastic seukemia B-ALL B-cell lymphoma BCL2A1 BCL6 benign bile acids Biofluid Biology of neoplasia Biomarker biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers biomarkers Bladder Bladder cancer Bladder Cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN blastoid morphology blindness Blood Brain breast cancer Breast Cancer Breast milk Breast Milk Burkitt lymphoma cancer genetics Cancer Genomics CAR T cell therapy CAR-T-cells Cardiovascular Disease Castleman Disease CD10 CD3 CD8 CDK46 inhibitors CDKN1A CDKN2A mutation Cell Free Plasma Cells Cerebrospinal Fluid Cetuximab Chemokines Childhood Atopic Dermatitis children chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor Circulating tumor cells classifications clinical trial cMET cognition Colon Colon cancer Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy cornea COVID-19 cultivated limbal epithelial cells Clec Custom mRNA CXCL12 cyclic AMP‑dependent transcription factor ATF‑4 Cytokine Cytokines Cytotoxic T Cells cytotoxicity dementia Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DLBCL COO DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Dysplasia ear Efficacy EGFR Muatations EMT Encephalophy end stage kidney disease Endothelial cell EPCORE NHL-1 epidemiology epidermal growth factor receptor EGFRHER Epigenetics epigenomics Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Extracellular Vesicles Evs extraction-free RNA workflow Fabry Disease farnesoid X receptorcholesterol Feasibility FFPE FGF Ligand Trap FGFR fibroblast growth factor receptor 4 Fibrous Tumors FOLFOX7 Follicular lymphoma gastrointestinal cancer GEIS gene expression Gene Expression Gene expression analysis gene expression profiling Gene Expression Profiling gene expression signature Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors HARMONIA clinical trial HCC Head and neck cancer Head and Neck Cancer Heart hepatocellular carcinoma HER-2 HER2 HER2- Histone Deacetylase Inhibitors HLA-E Homing HPV HR+ HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Path Assay HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay HTP Ibrutinib ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune microenvironment Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immuno-oncology agents immunohistochemistry IHC Immunologically hot tumours IMMUNOSARC Immunotherapy immunotherapy Inflammation Insulin Resistance Integrins Intrinsic subtypes inverted papilloma IRF4 IRS-1 ISG JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease KRAS Kruppel-like factor 5 Limb ischemia limbal stem cell deficiency LSCD Liposarcoma Liquid Biopsy Liver liver disease liver steatosis liver tissue Lung Lung cancer Lupus Lymph Node Metastasis lymphatic Lymphocytes Lymphoid Neoplasia Lymphoma lymphoma lymphomas Machine Learning machine learning malignancy sinonasal malignant mCRC Mechanism of Action Melanoma Mesothelioma MET metastatic colorectal cancer CRC Method Comparison Microenvironment MicroRNA microRNA miR-122-5p miR-3937 miRNA miRNA WTA miRNA-375 Molecular Characterization Mouse Mouse mRNA mouse mRNA TRP mRNA mRNA custom mTOR pathway mTOR signaling multi-omics multiple myeloma Multiple Myeloma MUM1 Muscle mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Neoantigens Nestin+ Neuroendocrine Tumor Neurologic nivolumab NKG2A Non-alcoholic fatty liver disease non-Hodgkin Lymphoma Non-Hodgkin lymphoma NHL Non-small cell lung cancer Novel Therapeutic Targets NTRK1 nuclease protection assay Obesity obesity OBP Oesophageal Adenocarcinoma Oncology Oncology-Biomarker OPSCC Optical imaging Oral cancer Oral Cancer Oral lesion Oral Squamous Cell Carcinoma Oropharyngeal Cancer Osteoarthritis Osteoclast Ovarian cancer PALLET PALOMA-2 PAM50 Predictive biomarkers Pan-Cancer PanB Pancreas Pancreatic Cancer Paralysis Parkinson's Disease Pathogenesis pathophysiology Pathway analysis Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PENELOPE-B PFAS PFNA PFOS Phase III PHOENIX trial PIK3CA mutation PIP Placenta placenta Plasma Plasma miRNAs Platform Comparison PMAIP1 population based Precision medicine Precision oncology predictive biology Predictive Biomarkers Predictive Modeling Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate Prostate Cancer prostate cancer prostate genomics Protein Protein Interaction network qNPA qPCR R-CHOP race disparities Radioimmunotherapy RAS Rearrangements Refractory DLBCL Relapsed DLBCL Renal Cell Carcinoma Renal Disease Reproductive Response rate RET Reveal Rhabdomyosarcoma RMS Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma sarcoma SARS-CoV-2 scoring system Sequencing Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures single cell Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium Squamous cell carcinoma squamous cell carcinoma STAT6 pathway Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid Synovial Sarcoma synthetic miRNA T cells T-Cell T-cells targeted therapeutics Technology Comparison Testicular cancer Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer Tislelizumab tislelizumab TMB TME tomentosin Toxicity TP53 mutation Transcriptome transcriptome profile transcriptome profiling Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma Uterus VEGFR vestibular schwannoma VS virus Wound healing Xenograft Tissue Zanubrutinib Zanubrutinlb2021
Page last updated February 01, 2023